A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MeRmaiD-1)
Administered By
Awarded By
Contributors
- Crawford, Jeffrey Principal Investigator
Start/End
- November 16, 2020 - October 31, 2025